Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.54 |
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | MMP9 | P14780 | 5/20 | 0.49 |
| ▸ | MMP7 | P09237 | 4/20 | 0.49 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025844 | 1.00 | MMP1 (0.54) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL14045787 | 0.85 | SLC1A3 (0.42) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL4925808 | 0.83 | ADAM17 (0.60) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL14025842 | 0.83 | ADAM17 (0.60) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL20998631 | 0.76 | ALDH1A1 (0.50) | MMP1MMP13MMP9MMP8MMP2 | |
| SCHEMBL4927229 | 0.76 | MMP1 (0.47) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL5182142 | 0.76 | MMP1 (0.47) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL1770811 | 0.74 | MMP1 (0.67) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL12649188 | 0.74 | MMP1 (0.67) | MMP1ADAM17MMP13MMP9MMP7 | |
| SCHEMBL4916984 | 0.73 | MMP9 (0.60) | MMP1ADAM17MMP13MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP1 387/4885ADAM17 1884/4885MMP13 781/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP1 510/4885ADAM17 2174/4885MMP13 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.